Literature DB >> 12971431

Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

M Ries1, E Mengel, G Kutschke, K S Kim, F Birklein, F Krummenauer, M Beck.   

Abstract

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971431     DOI: 10.1023/a:1025127723729

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  3 in total

Review 1.  Treatment options in postherpetic neuralgia.

Authors:  C Bonezzi; L Demartini
Journal:  Acta Neurol Scand Suppl       Date:  1999

2.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

Review 3.  Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy.

Authors:  I W Tremont-Lukats; C Megeff; M M Backonja
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

  3 in total
  12 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 2.  [Fabry disease : diagnosis and treatment].

Authors:  N Üçeyler; C Sommer
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 3.  Neuropathic pain in children: Special considerations.

Authors:  Gary A Walco; Robert H Dworkin; Elliot J Krane; Alyssa A LeBel; Rolf-Detlef Treede
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

4.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Authors:  B Hoffmann; A Garcia de Lorenzo; A Mehta; M Beck; U Widmer; R Ricci
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

Review 5.  [Pain therapy for Fabry's disease].

Authors:  C Sommer; N Uçeyler; T Duning; K Arning; R Baron; E Brand; S Canaan-Kühl; M Hilz; D Naleschinski; C Wanner; F Weidemann
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

6.  Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.

Authors:  Alessandro Salviati; Alessandro P Burlina; Walter Borsini
Journal:  Neurol Sci       Date:  2010-03-19       Impact factor: 3.307

7.  The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.

Authors:  Markus Ries; Uma Ramaswami; Rossella Parini; Bengt Lindblad; Catharina Whybra; Ingrid Willers; Andreas Gal; Michael Beck
Journal:  Eur J Pediatr       Date:  2003-09-20       Impact factor: 3.183

Review 8.  Fabry disease in infancy and early childhood: a systematic literature review.

Authors:  Dawn A Laney; Dawn S Peck; Andrea M Atherton; Linda P Manwaring; Katherine M Christensen; Suma P Shankar; Dorothy K Grange; William R Wilcox; Robert J Hopkin
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

Review 9.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

Review 10.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.